News

March 9, 2018March 9, 2018

PET Scans Could Identify Those Likely to Respond to PD-1-targeted Cancer Therapies

News

PET scans could be a non-invasive way to identify patients likely to respond to cancer therapies targeting the PD-1 and PD-L1 proteins. Bristol-Myers Squibb developed the approach. It allows scientists to ... Read more

March 8, 2018March 8, 2018

New Dosing Schedule Allows Patients to Receive Opdivo Every Four Weeks

News

The U.S. Food and Drug Administration (FDA) has approved a new dosing schedule for Opdivo (nivolumab), allowing the medicine to be offered every four weeks in addition to the previously available ... Read more

March 7, 2018March 7, 2018

Britain’s NICE Recommends That Bavencio Be Covered for Merkel Cell Carcinoma

News

Britain’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service cover Bavencio (avelumab) as a treatment for adults with metastatic Merkel cell carcinoma (mMCC), a rare ... Read more

March 6, 2018March 7, 2018

Application Helps Researchers Gain Access to Charles River’s Tumor Model Information

News

Charles River Laboratories has created an application to help cancer researchers obtain access to information on tumor models it has developed. The objective is to help these scientists design efficient cell-culture ... Read more

March 5, 2018March 5, 2018

Fate Receives $4 Million to Advance Natural Killer Cell Immunotherapy Into Trials

News

The California Institute for Regenerative Medicine has given Fate Therapeutics a $4 million grant to advance its natural killer cell immunotherapy FT516 into clinical trials. At the heart of Fate’s therapy is engineering white blood cells ... Read more

March 2, 2018October 22, 2018

Advanced NSCLC Patients Again Being Enrolled in Phase 3 Trial of Tedopi

News

A Phase 3 trial assessing the ability of Tedopi to treat people with advanced non-small cell lung cancer (NSCLC) who failed to respond to prior therapy can again enroll patients — ... Read more

March 1, 2018March 1, 2018

Immunotherapy Bavencio Fails to Outperform Chemo in Lung Cancer Trial

News

The immune checkpoint inhibitor Bavencio (avelumab) failed to do a better job than the chemotherapy Taxotere (docetaxel) at improving lung cancer patients’ survival, a Phase 3 clinical trial shows. Those in ... Read more

February 28, 2018March 1, 2018

Kite and Sagamo Are Partnering on Cell-engineered Treatments for Cancer

News

Kite Pharma and Sagamo Therapeutics are combining the proprietary cell-engineering strategies that each is known for, to develop treatments for cancer. In Kite’s case, the strategy is gene therapy. In Sagamo’s ... Read more

February 27, 2018February 27, 2018

Re-engineered Cold Virus Increases Brain Cancer Patients’ Survival, Phase 1 Trial Shows

News

Re-engineering a common cold virus to attack the deadliest kind of brain tumor extended the survival of patients whose tumor returned after various treatments, including surgery, a Phase 1 clinical ... Read more

February 26, 2018February 26, 2018

Bristol-Myers, Nektar Developing Cancer Therapy to Be Used with Checkpoint Inhibitors

News

Bristol-Myers Squibb and Nektar Therapeutics are working together on a cancer therapy that can be used in combination with immune checkpoint inhibitors Bristol-Meyers is developing. The hope is that the therapy, NKTR-214, can ... Read more